Edgewise Therapeutics Inc EWTX

$39.06 -0.17 (-0.43%)

Valuation

Market cap
4,242,072,000
Revenue TTM
$0
Net income TTM
$-167,800,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,062,600
Avg volume
1,477,444
Day's range
$38.93 – $40.41
Shares out
108,604,000
Stochastic %K
37%
Beta
0.35
Analysts
Strong Sell
Price target
$52.62

Price

Company profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a...

Show more

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Industry
Biotechnology
Sector
Healthcare
Phone
720 262 7002
Website
https://edgewisetx.com
Address
1715 38th Street, Boulder, United States

Latest news

Stocktwits

Kostcoboi Oct 11, 2:49 PM
$BMY $CYTK $EWTX $TNYA this reinforces that $TNYA’s TN-201 occupies a narrower, genetically-defined niche rather than going head-to-head with the two approved blockbuster-track drugs. which is actually a reasonable position (less direct competition for a specific patient subset) rather than a weakness. It’s also a fix to the problem rather than managing the problem like what $BMY is doing. $TNYA’s TN 201 holds EMA PRIME designation in Europe and FDA Fast Track / Rare Disease Evidence Principles engagement in the United States.
0 replies
Merlintrader Oct 11, 9:33 AM
HCM Catalysts: $EWTX vs $CYTK $BMY $TNYA Edgewise, Cytokinetics, Bristol Myers Squibb and Tenaya share an HCM focus, not an interchangeable clinical opportunity. We compare obstructive, nonobstructive and genetically selected disease, pivotal plans, evidence and ownership changes. TN-201 is a genetically restricted early-stage alternative. Full comparative research: https://www.merlintrader.com/ewtx-cytk-bmy-tnya-hcm-catalyst-comparison/
1 replies
Merlintrader Oct 10, 10:10 PM
$EWTX: after the Servier sale, Edgewise's owned pipeline is cardiovascular. Our hub examines EDG-7500, EDG-15400 and the conditional milestones tied to the divested muscle-disease business. https://www.merlintrader.com/edgewise-therapeutics-stock-hub/
0 replies
S_Franconi Oct 8, 12:49 PM
$EWTX Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 https://investors.edgewisetx.com/news/news-details/2026/Edgewise-Therapeutics-Doses-First-Patient-in-Phase-2-EQUINOX-HFpEF-Trial-of-EDG-15400/default.aspx
0 replies
Avocado_smash Sep 30, 2:28 AM
$EWTX
0 replies
Trainguy1 Sep 24, 11:42 AM
$EWTX This past Tuesday, Sept 22, 2026, Edgewise Therapeutics presented the Mechanisms of Action utilized by EDG-7500 for treating Hypertrophic Cardiomyopathy. Refer to pg 39 in the presentation (linked below) to see the complete MoA. EWTX will physically demonstrate EDG-7500’s effectiveness in a ph3 clinical trial, to be initiated by the end of this year. The trial’s duration is yet to be identified. HCM affects about 700,000 Americans, and about 15 million people worldwide. https://s204.q4cdn.com/663829792/files/doc_events/2026/Sep/22/Sept-22-Edgewise-Investor-EDG-7500-MOA-slides_vfinal.pdf
0 replies
STRelativeStrength Sep 17, 5:50 PM
$EWTX undiscovered breakout with 661 watchers
1 replies
droog_botski Sep 17, 3:39 PM
$EWTX Is a buyout or partnership advancing ?
1 replies